
NICE approves Fasenra® for EGPA
The National Institute for Health and Care Excellence (NICE) has officially recommended benralizumab (Fasenra) as a new treatment option for adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).




